Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Slo-niacin for hyperphosphataemia in haemodialysis patients
ACTRN12611000500954Phase 3Completed
- Sponsor
- Dr. Ken-Soon Tan
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of niacin in hyperphosphatemia, chronic kidney disease-mineral and bone disorder (CKD-MBD) and end-stage kidney disease (ESKD), sponsored by Dr. Ken-Soon Tan. Primary endpoint: Serum phosphate. Started Jun 2011; status: completed.
02
Drugs
niacin
03
Conditions
hyperphosphatemiachronic kidney disease-mineral and bone disorder (CKD-MBD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ACTRN12611000500954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000500954.